CONMED Corporation Logo

CONMED Corporation

CNMD

(1.5)
Stock Price

72,24 USD

11.65% ROA

11.71% ROE

20x PER

Market Cap.

1.972.458.614,00 USD

109.53% DER

1.25% Yield

7.74% NPM

CONMED Corporation Stock Analysis

CONMED Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CONMED Corporation Fundamental Stock Analysis
# Analysis Rating
1 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

2 ROE

The stock's ROE falls within an average range (7.54%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (6.79%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

5 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (2.586) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

6 PBV

The stock's elevated P/BV ratio (4.15x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 DER

The stock is burdened with a heavy load of debt (127%), making it financially unstable and potentially risky for investors.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

CONMED Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CONMED Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

CONMED Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CONMED Corporation Revenue
Year Revenue Growth
1986 10.500.000
1987 12.500.000 16%
1988 14.200.000 11.97%
1989 19.900.000 28.64%
1990 31.400.000 36.62%
1991 38.500.000 18.44%
1992 42.600.000 9.62%
1993 53.600.000 20.52%
1994 71.100.000 24.61%
1995 99.600.000 28.61%
1996 125.600.000 20.7%
1997 138.300.000 9.18%
1998 336.400.000 58.89%
1999 372.600.000 9.72%
2000 392.230.000 5%
2001 428.722.000 8.51%
2002 453.062.000 5.37%
2002 453.062.000 0%
2003 497.130.000 8.86%
2004 558.388.000 10.97%
2005 617.305.000 9.54%
2006 646.812.000 4.56%
2007 694.288.000 6.84%
2008 742.183.000 6.45%
2009 694.739.000 -6.83%
2010 713.723.000 2.66%
2011 725.077.000 1.57%
2012 767.140.000 5.48%
2013 756.755.000 -1.37%
2014 734.467.000 -3.03%
2015 719.168.000 -2.13%
2016 763.520.000 5.81%
2017 796.392.000 4.13%
2018 859.634.000 7.36%
2019 955.097.000 10%
2020 862.459.000 -10.74%
2021 1.010.635.000 14.66%
2022 1.045.472.000 3.33%
2023 1.218.312.000 14.19%
2023 1.240.954.000 1.82%
2024 1.322.992.000 6.2%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CONMED Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 2.400.000 100%
1995 2.800.000 14.29%
1996 3.000.000 6.67%
1997 3.000.000 0%
1998 12.000.000 75%
1999 12.100.000 0.83%
2000 14.870.000 18.63%
2001 14.830.000 -0.27%
2002 16.087.000 7.81%
2002 16.087.000 0%
2003 17.306.000 7.04%
2004 20.205.000 14.35%
2005 25.469.000 20.67%
2006 30.715.000 17.08%
2007 30.400.000 -1.04%
2008 33.108.000 8.18%
2009 31.837.000 -3.99%
2010 29.652.000 -7.37%
2011 28.651.000 -3.49%
2012 28.214.000 -1.55%
2013 25.831.000 -9.23%
2014 27.779.000 7.01%
2015 27.436.000 -1.25%
2016 32.254.000 14.94%
2017 32.307.000 0.16%
2018 42.188.000 23.42%
2019 45.460.000 7.2%
2020 40.473.000 -12.32%
2021 43.565.000 7.1%
2022 47.152.000 7.61%
2023 49.856.000 5.42%
2023 52.602.000 5.22%
2024 56.392.000 6.72%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CONMED Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1986 3.300.000
1987 3.900.000 15.38%
1988 5.000.000 22%
1989 6.900.000 27.54%
1990 10.100.000 31.68%
1991 11.900.000 15.13%
1992 14.300.000 16.78%
1993 25.300.000 43.48%
1994 21.000.000 -20.48%
1995 25.600.000 17.97%
1996 31.600.000 18.99%
1997 35.300.000 10.48%
1998 93.600.000 62.29%
1999 107.200.000 12.69%
2000 124.673.000 14.02%
2001 140.560.000 11.3%
2002 141.735.000 0.83%
2002 141.735.000 0%
2003 157.453.000 9.98%
2004 183.183.000 14.05%
2005 216.685.000 15.46%
2006 234.832.000 7.73%
2007 240.541.000 2.37%
2008 272.437.000 11.71%
2009 266.310.000 -2.3%
2010 276.463.000 3.67%
2011 277.707.000 0.45%
2012 302.469.000 8.19%
2013 310.730.000 2.66%
2014 293.942.000 -5.71%
2015 303.091.000 3.02%
2016 338.400.000 10.43%
2017 351.799.000 3.81%
2018 355.617.000 1.07%
2019 400.141.000 11.13%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CONMED Corporation EBITDA
Year EBITDA Growth
1986 1.700.000
1987 2.100.000 19.05%
1988 1.500.000 -40%
1989 1.200.000 -25%
1990 6.000.000 80%
1991 7.900.000 24.05%
1992 7.700.000 -2.6%
1993 1.600.000 -381.25%
1994 12.800.000 87.5%
1995 23.800.000 46.22%
1996 32.000.000 25.63%
1997 69.200.000 53.76%
1998 84.800.000 18.4%
1999 100.500.000 15.62%
2000 93.951.000 -6.97%
2001 99.106.000 5.2%
2002 101.719.000 2.57%
2002 101.719.000 0%
2003 125.770.000 19.12%
2004 111.197.000 -13.11%
2005 101.653.000 -9.39%
2006 77.828.000 -30.61%
2007 111.540.000 30.22%
2008 107.595.000 -3.67%
2009 69.552.000 -54.7%
2010 98.900.000 29.67%
2011 111.263.000 11.11%
2012 111.826.000 0.5%
2013 104.375.000 -7.14%
2014 98.520.000 -5.94%
2015 95.054.000 -3.65%
2016 90.043.000 -5.57%
2017 46.935.000 -91.85%
2018 71.305.000 34.18%
2019 73.926.000 3.55%
2020 45.655.000 -61.92%
2021 108.590.000 57.96%
2022 -41.957.000 358.81%
2023 121.200.000 134.62%
2023 182.186.000 33.47%
2024 199.908.000 8.87%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CONMED Corporation Gross Profit
Year Gross Profit Growth
1986 5.000.000
1987 6.100.000 18.03%
1988 6.700.000 8.96%
1989 8.200.000 18.29%
1990 16.100.000 49.07%
1991 20.100.000 19.9%
1992 22.300.000 9.87%
1993 26.700.000 16.48%
1994 36.200.000 26.24%
1995 52.200.000 30.65%
1996 66.600.000 21.62%
1997 71.100.000 6.33%
1998 190.400.000 62.66%
1999 219.800.000 13.38%
2000 233.494.000 5.86%
2001 224.348.000 -4.08%
2002 237.171.000 5.41%
2002 237.171.000 0%
2003 259.697.000 8.67%
2004 286.892.000 9.48%
2005 313.021.000 8.35%
2006 312.846.000 -0.06%
2007 349.125.000 10.39%
2008 382.381.000 8.7%
2009 337.332.000 -13.35%
2010 365.384.000 7.68%
2011 374.934.000 2.55%
2012 405.843.000 7.62%
2013 406.468.000 0.15%
2014 398.469.000 -2.01%
2015 381.702.000 -4.39%
2016 408.330.000 6.52%
2017 431.041.000 5.27%
2018 469.110.000 8.12%
2019 524.715.000 10.6%
2020 460.300.000 -13.99%
2021 568.036.000 18.97%
2022 571.245.000 0.56%
2023 672.236.000 15.02%
2023 643.067.000 -4.54%
2024 692.616.000 7.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CONMED Corporation Net Profit
Year Net Profit Growth
1986 700.000
1987 1.100.000 36.36%
1988 800.000 -37.5%
1989 -300.000 366.67%
1990 2.400.000 112.5%
1991 3.900.000 38.46%
1992 4.100.000 4.88%
1993 -1.400.000 392.86%
1994 5.400.000 125.93%
1995 10.900.000 50.46%
1996 16.300.000 33.13%
1997 -7.100.000 329.58%
1998 17.800.000 139.89%
1999 27.200.000 34.56%
2000 19.314.000 -40.83%
2001 24.406.000 20.86%
2002 34.151.000 28.54%
2002 34.151.000 0%
2003 32.082.000 -6.45%
2004 33.465.000 4.13%
2005 31.994.000 -4.6%
2006 -12.507.000 355.81%
2007 41.456.000 130.17%
2008 44.561.000 6.97%
2009 12.137.000 -267.15%
2010 30.346.000 60%
2011 752.000 -3935.37%
2012 40.481.000 98.14%
2013 35.939.000 -12.64%
2014 32.192.000 -11.64%
2015 30.498.000 -5.55%
2016 14.664.000 -107.98%
2017 55.487.000 73.57%
2018 40.854.000 -35.82%
2019 28.620.000 -42.75%
2020 9.517.000 -200.73%
2021 62.542.000 84.78%
2022 -80.582.000 177.61%
2023 63.348.000 227.21%
2023 64.459.000 1.72%
2024 119.904.000 46.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CONMED Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 1 0%
1996 1 0%
1997 0 0%
1998 1 0%
1999 1 100%
2000 1 0%
2001 1 100%
2002 1 0%
2002 1 0%
2003 1 0%
2004 1 0%
2005 1 0%
2006 0 0%
2007 1 100%
2008 2 0%
2009 0 0%
2010 1 100%
2011 0 0%
2012 1 100%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 2 100%
2018 1 0%
2019 1 0%
2020 0 0%
2021 2 100%
2022 -3 200%
2023 2 200%
2023 2 0%
2024 4 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CONMED Corporation Free Cashflow
Year Free Cashflow Growth
1990 1.900.000
1991 -300.000 733.33%
1992 -1.500.000 80%
1993 4.200.000 135.71%
1994 6.100.000 31.15%
1995 -100.000 6200%
1996 21.000.000 100.48%
1997 23.600.000 11.02%
1998 -23.800.000 199.16%
1999 -12.900.000 -84.5%
2000 21.900.000 158.9%
2001 62.706.000 65.08%
2002 31.539.000 -98.82%
2002 31.539.000 0%
2003 48.701.000 35.24%
2004 62.421.000 21.98%
2005 26.192.000 -138.32%
2006 42.677.000 38.63%
2007 44.984.000 5.13%
2008 25.270.000 -78.01%
2009 3.584.000 -605.08%
2010 23.511.000 84.76%
2011 81.250.000 71.06%
2012 73.667.000 -10.29%
2013 62.504.000 -17.86%
2014 49.765.000 -25.6%
2015 33.059.000 -50.53%
2016 23.469.000 -40.86%
2017 52.724.000 55.49%
2018 58.194.000 9.4%
2019 75.067.000 22.48%
2020 51.518.000 -45.71%
2021 96.904.000 46.84%
2022 11.580.000 -736.82%
2023 106.316.000 89.11%
2023 40.733.000 -161.01%
2024 39.716.000 -2.56%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CONMED Corporation Operating Cashflow
Year Operating Cashflow Growth
1990 5.200.000
1991 1.400.000 -271.43%
1992 3.600.000 61.11%
1993 5.700.000 36.84%
1994 8.300.000 31.33%
1995 5.100.000 -62.75%
1996 25.900.000 80.31%
1997 31.800.000 18.55%
1998 21.000.000 -51.43%
1999 37.000.000 43.24%
2000 35.950.000 -2.92%
2001 77.149.000 53.4%
2002 44.923.000 -71.74%
2002 44.923.000 0%
2003 58.010.000 22.56%
2004 74.840.000 22.49%
2005 42.434.000 -76.37%
2006 64.572.000 34.28%
2007 65.894.000 2.01%
2008 61.149.000 -7.76%
2009 25.028.000 -144.32%
2010 38.243.000 34.56%
2011 102.993.000 62.87%
2012 95.199.000 -8.19%
2013 80.949.000 -17.6%
2014 65.176.000 -24.2%
2015 48.068.000 -35.59%
2016 38.222.000 -25.76%
2017 65.566.000 41.7%
2018 74.701.000 12.23%
2019 95.133.000 21.48%
2020 64.531.000 -47.42%
2021 111.770.000 42.26%
2022 33.365.000 -234.99%
2023 125.348.000 73.38%
2023 46.127.000 -171.75%
2024 43.306.000 -6.51%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CONMED Corporation Capital Expenditure
Year Capital Expenditure Growth
1990 3.300.000
1991 1.700.000 -94.12%
1992 5.100.000 66.67%
1993 1.500.000 -240%
1994 2.200.000 31.82%
1995 5.200.000 57.69%
1996 4.900.000 -6.12%
1997 8.200.000 40.24%
1998 44.800.000 81.7%
1999 49.900.000 10.22%
2000 14.050.000 -255.16%
2001 14.443.000 2.72%
2002 13.384.000 -7.91%
2002 13.384.000 0%
2003 9.309.000 -43.77%
2004 12.419.000 25.04%
2005 16.242.000 23.54%
2006 21.895.000 25.82%
2007 20.910.000 -4.71%
2008 35.879.000 41.72%
2009 21.444.000 -67.31%
2010 14.732.000 -45.56%
2011 21.743.000 32.24%
2012 21.532.000 -0.98%
2013 18.445.000 -16.74%
2014 15.411.000 -19.69%
2015 15.009.000 -2.68%
2016 14.753.000 -1.74%
2017 12.842.000 -14.88%
2018 16.507.000 22.2%
2019 20.066.000 17.74%
2020 13.013.000 -54.2%
2021 14.866.000 12.46%
2022 21.785.000 31.76%
2023 19.032.000 -14.47%
2023 5.394.000 -252.84%
2024 3.590.000 -50.25%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CONMED Corporation Equity
Year Equity Growth
1986 3.900.000
1987 10.100.000 61.39%
1988 10.900.000 7.34%
1989 10.300.000 -5.83%
1990 12.800.000 19.53%
1991 34.000.000 62.35%
1992 38.700.000 12.14%
1993 37.500.000 -3.2%
1994 43.100.000 12.99%
1995 75.000.000 42.53%
1996 158.600.000 52.71%
1997 162.700.000 2.52%
1998 182.200.000 10.7%
1999 211.300.000 13.77%
2000 230.603.000 8.37%
2001 283.634.000 18.7%
2002 386.939.000 26.7%
2002 386.939.000 0%
2003 433.490.000 10.74%
2004 447.983.000 3.24%
2005 453.006.000 1.11%
2006 440.354.000 -2.87%
2007 505.002.000 12.8%
2008 531.734.000 5.03%
2009 576.515.000 7.77%
2010 586.563.000 1.71%
2011 573.071.000 -2.35%
2012 606.998.000 5.59%
2013 606.319.000 -0.11%
2014 581.298.000 -4.3%
2015 585.073.000 0.65%
2016 580.576.000 -0.77%
2017 631.432.000 8.05%
2018 662.270.000 4.66%
2019 710.467.000 6.78%
2020 709.038.000 -0.2%
2021 785.435.000 9.73%
2022 745.545.000 -5.35%
2023 834.222.000 10.63%
2023 796.205.000 -4.77%
2024 881.832.000 9.71%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CONMED Corporation Assets
Year Assets Growth
1986 6.400.000
1987 13.000.000 50.77%
1988 13.500.000 3.7%
1989 21.900.000 38.36%
1990 22.200.000 1.35%
1991 38.300.000 42.04%
1992 41.900.000 8.59%
1993 57.300.000 26.88%
1994 62.100.000 7.73%
1995 119.400.000 47.99%
1996 170.100.000 29.81%
1997 561.600.000 69.71%
1998 628.800.000 10.69%
1999 662.200.000 5.04%
2000 679.571.000 2.56%
2001 701.608.000 3.14%
2002 742.140.000 5.46%
2002 742.140.000 0%
2003 805.058.000 7.82%
2004 872.825.000 7.76%
2005 903.783.000 3.43%
2006 861.571.000 -4.9%
2007 893.951.000 3.62%
2008 931.661.000 4.05%
2009 957.503.000 2.7%
2010 985.773.000 2.87%
2011 935.594.000 -5.36%
2012 1.084.462.000 13.73%
2013 1.090.508.000 0.55%
2014 1.098.194.000 0.7%
2015 1.112.944.000 1.33%
2016 1.328.983.000 16.26%
2017 1.357.961.000 2.13%
2018 1.369.138.000 0.82%
2019 1.775.095.000 22.87%
2020 1.751.673.000 -1.34%
2021 1.766.017.000 0.81%
2022 2.297.592.000 23.14%
2023 2.300.021.000 0.11%
2023 2.325.675.000 1.1%
2024 2.285.616.000 -1.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CONMED Corporation Liabilities
Year Liabilities Growth
1986 2.500.000
1987 2.900.000 13.79%
1988 2.600.000 -11.54%
1989 11.600.000 77.59%
1990 9.400.000 -23.4%
1991 4.300.000 -118.6%
1992 3.200.000 -34.38%
1993 19.800.000 83.84%
1994 19.000.000 -4.21%
1995 44.400.000 57.21%
1996 11.500.000 -286.09%
1997 398.900.000 97.12%
1998 446.600.000 10.68%
1999 450.900.000 0.95%
2000 448.968.000 -0.43%
2001 417.974.000 -7.42%
2002 355.201.000 -17.67%
2002 355.201.000 0%
2003 371.568.000 4.4%
2004 424.842.000 12.54%
2005 450.777.000 5.75%
2006 421.217.000 -7.02%
2007 388.949.000 -8.3%
2008 399.927.000 2.75%
2009 380.988.000 -4.97%
2010 399.210.000 4.56%
2011 362.523.000 -10.12%
2012 477.464.000 24.07%
2013 484.189.000 1.39%
2014 516.896.000 6.33%
2015 527.871.000 2.08%
2016 748.407.000 29.47%
2017 726.529.000 -3.01%
2018 706.868.000 -2.78%
2019 1.064.628.000 33.6%
2020 1.042.635.000 -2.11%
2021 980.582.000 -6.33%
2022 1.552.047.000 36.82%
2023 1.465.799.000 -5.88%
2023 1.529.470.000 4.16%
2024 1.403.784.000 -8.95%

CONMED Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
41.35
Net Income per Share
3.2
Price to Earning Ratio
20x
Price To Sales Ratio
1.55x
POCF Ratio
11.27
PFCF Ratio
12.4
Price to Book Ratio
2.24
EV to Sales
2.28
EV Over EBITDA
14.83
EV to Operating CashFlow
16.63
EV to FreeCashFlow
18.29
Earnings Yield
0.05
FreeCashFlow Yield
0.08
Market Cap
1,97 Bil.
Enterprise Value
2,91 Bil.
Graham Number
45.39
Graham NetNet
-33.57

Income Statement Metrics

Net Income per Share
3.2
Income Quality
1.77
ROE
0.12
Return On Assets
0.04
Return On Capital Employed
0.08
Net Income per EBT
0.8
EBT Per Ebit
0.81
Ebit per Revenue
0.12
Effective Tax Rate
0.2

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.54
Operating Profit Margin
0.12
Pretax Profit Margin
0.1
Net Profit Margin
0.08

Dividends

Dividend Yield
0.01
Dividend Yield %
1.25
Payout Ratio
0.25
Dividend Per Share
0.8

Operating Metrics

Operating Cashflow per Share
5.68
Free CashFlow per Share
5.16
Capex to Operating CashFlow
0.09
Capex to Revenue
0.01
Capex to Depreciation
0.26
Return on Invested Capital
0.07
Return on Tangible Assets
0.12
Days Sales Outstanding
68.54
Days Payables Outstanding
63.04
Days of Inventory on Hand
200.62
Receivables Turnover
5.33
Payables Turnover
5.79
Inventory Turnover
1.82
Capex per Share
0.52

Balance Sheet

Cash per Share
0,94
Book Value per Share
28,62
Tangible Book Value per Share
-18.1
Shareholders Equity per Share
28.62
Interest Debt per Share
32.6
Debt to Equity
1.1
Debt to Assets
0.42
Net Debt to EBITDA
4.78
Current Ratio
2.34
Tangible Asset Value
-0,56 Bil.
Net Current Asset Value
-0,78 Bil.
Invested Capital
1913955001
Working Capital
0,36 Bil.
Intangibles to Total Assets
0.63
Average Receivables
0,24 Bil.
Average Payables
0,10 Bil.
Average Inventory
322327500
Debt to Market Cap
0.49

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CONMED Corporation Dividends
Year Dividends Growth
2012 1
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%
2024 1 0%

CONMED Corporation Profile

About CONMED Corporation

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CEO
Mr. Curt R. Hartman
Employee
4.000
Address
11311 Concept Boulevard
Largo, 33773-4908

CONMED Corporation Executives & BODs

CONMED Corporation Executives & BODs
# Name Age
1 Mr. Peter K. Shagory
Executive Vice President of Strategy & Corporate Development
70
2 Mr. David R. Murray
President of ConMed Electrosurgery
70
3 Mr. Todd W. Garner
Executive Vice President, Chief Financial Officer & Principal Accounting Officer
70
4 Mr. Patrick J. Beyer
Chief Operating Officer
70
5 Mr. Daniel S. Jonas Esq.
Special Counsel & Corporate Secretary
70
6 Mr. John Ferrell
Executive Vice President of Human Resources
70
7 Mr. Stanley W. Peters III
President of Advanced Surgical & Advanced Endoscopic Technologies
70
8 Mr. Richard Glaze
Chief Information Officer
70
9 Mr. Curt R. Hartman
Chairman of the Board, Chief Executive Officer & President
70
10 Ms. Shanna L. Cotti-Osmanski
Executive Vice President of Information Technology & Chief Information Officer
70

CONMED Corporation Competitors